Accordingly, therapeutic blockade of FASN activity may be effective in the prevention of refractoriness to endocrine therapy in HER2-negative breast carcinomas subtypes where FASN overexpression results from HER2/HER3 signaling. This evidence concerns the gene ERBB3 and breast carcinoma.